![]() | |
Names | |
---|---|
Preferred IUPAC name 25-Ethyl-14-fluoro-22-hydroxy-82-propyl-3,7,9-trioxa-1,10(1),2(1,4),8(1,3)-tetrabenzenadecaphane-102-carboxylic acid | |
Other names LY293111 VML 295 | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider |
|
KEGG |
|
UNII | |
| |
| |
Properties | |
C33H33FO6 | |
Molar mass | 544.619 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). |
Etalocib is a drug candidate that was under development for the treatment of various types of cancer.[1] It acts as aleukotriene B4 receptorantagonist and aPPARγ agonist.[2]
Clinical trials were conducted measuring efficacy for treatment ofnon-small cell lung cancer andpancreatic cancer and the inflammatory conditionsasthma,psoriasis, andulcerative colitis, but were suspended due to lack of efficacy.[3]
![]() | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |